

### In the Claims

Claims 1 – 12 (Cancelled)

13. (Currently Amended) A method of decreasing intratumoral vessels to inhibit growth of melanoma and pulmonary metastases in a mammal comprising:

administering to the mammal a therapeutically effective amount of a nucleic acid molecule comprising ~~[[a]]~~ the polynucleotide sequence of shown in SEQ ID NO: 1.

14. (Previously Presented) The method according to claim 13, wherein the nucleic acid molecule is inserted into an expression vector.

15. (Currently Amended) The method according to claim 14, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express ~~all or part of a~~ the disintegrin domain encoded by the polynucleotide sequence shown in SEQ ID NO: 1 *in vivo*.

16. (Currently Amended) The method according to claim 15, wherein the disintegrin domain is Met-4201 to Glu-51491 shown in SEQ ID NO: 2 of metargidin.

17. (Currently Amended) A method of treating melanoma in a mammal comprising decreasing intratumoral vessels to inhibit growth of the melanoma by administering a therapeutically effective amount of a nucleic acid molecule comprising ~~[[a]]~~ the polynucleotide sequence of shown in SEQ ID N[[o.]]O: 1.

18. (Previously Presented) The method according to claim 17, wherein the nucleic acid molecule is inserted into an expression vector.

19. (Currently Amended) The method according to claim 18, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express ~~all or part of a~~ the disintegrin domain encoded by the polynucleotide sequence shown in SEQ ID NO: 1 *in vivo*.

20. (Currently Amended) A method according to claim 19, wherein the disintegrin domain is Met-420<sub>1</sub> to Glu-511<sub>91</sub> shown in SEQ ID NO: 2 ~~of metargidin~~.

21. (Currently Amended) A method of treating pulmonary metastases in a mammal comprising inhibiting the metatases by decreasing intratumoral vessels by administering a therapeutically effective amount of a nucleic acid molecule comprising [[a]] the polynucleotide sequence of shown in SEQ ID NO. 1.

22. (Previously Presented) The method according to claim 21, wherein the nucleic acid molecule is inserted into an expression vector.

23. (Currently Amended) The method according to claim 24, wherein the disintegrin domain is Met-420<sub>1</sub> to Glu-511<sub>91</sub> shown in SEQ ID NO: 2 ~~of metargidin~~.

24. (Currently Amended) The method according to claim 22, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express ~~all or part of a~~ the disintegrin domain encoded by the polynucleotide sequence shown in SEQ ID NO: 1 in vivo.